• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发/难治性惰性非霍奇金淋巴瘤患者未满足的需求及与健康相关的生活质量:一项混合方法研究

Unmet Needs and Health-Related Quality of Life Among Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: A Mixed-Methods Study.

作者信息

Sugimoto Miki, Yagasaki Kaori, Matsuki Eri, Shimizu Takayuki, Sakurai Masatoshi, Kataoka Keisuke, Doorenbos Ardith Z

机构信息

Graduate School of Health Management, Keio University, Tokyo, Japan.

Faculty of Nursing and Medical care, Keio University, Tokyo, Japan.

出版信息

Psychooncology. 2025 Feb;34(2):e70103. doi: 10.1002/pon.70103.

DOI:10.1002/pon.70103
PMID:39915950
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11803132/
Abstract

OBJECTIVE

Patients with relapsed or refractory (r/r) indolent non-Hodgkin lymphoma (iNHL) live with incurable disease for a long-term, experiencing multiple relapses and treatments that impair their health-related quality of life (HRQOL). We aimed to better understand the unmet needs and HRQOL of patients with r/r iNHL.

METHODS

This convergent mixed-methods study evaluated patients with r/r iNHL who received treatment. Unmet needs and HRQOL were assessed quantitatively using self-administered questionnaires and analyzed statistically. Qualitative data were collected through face-to-face semi-structured interviews for reflexive thematic analysis. Quantitative and qualitative findings were integrated through narrative discussion and joint display.

RESULTS

Questionnaire respondents (50 participants, mean age: 72.42 years) reported unmet needs in the health system and information and psychological domains and a negative association between unmet needs and HRQOL. Interviews (20 participants, mean age: 72.75 years) identified four themes: "unremarkable symptoms," "anxiety of progression in the near future," "make the best of life," and "means to live with uncertainty." Integration revealed that participants accepted their low HRQOL and attempted to make the best of life, influencing their perception of unmet needs.

CONCLUSIONS

Throughout the long course of r/r and repeated treatment, patients with iNHL accepted their low HRQOL, valued their current situations, and endeavored to make the best of life. In this situation, support in the psychological and health system and information domains is crucial. Support for the unmet needs of patients with r/r iNHL is essential as they strive to live their best lives while maintaining a favorable HRQOL.

摘要

目的

复发或难治性(r/r)惰性非霍奇金淋巴瘤(iNHL)患者长期患有无法治愈的疾病,经历多次复发和治疗,这损害了他们的健康相关生活质量(HRQOL)。我们旨在更好地了解r/r iNHL患者未满足的需求和HRQOL。

方法

这项收敛性混合方法研究评估了接受治疗的r/r iNHL患者。使用自填式问卷对未满足的需求和HRQOL进行定量评估,并进行统计分析。通过面对面的半结构化访谈收集定性数据,进行反思性主题分析。通过叙述性讨论和联合展示将定量和定性研究结果整合起来。

结果

问卷受访者(50名参与者,平均年龄:72.42岁)报告了在医疗系统、信息和心理领域存在未满足的需求,且未满足的需求与HRQOL之间存在负相关。访谈(20名参与者,平均年龄:72.75岁)确定了四个主题:“症状不明显”、“近期病情进展的焦虑”、“充分利用生活”和“在不确定性中生活的方式”。整合结果显示,参与者接受了较低的HRQOL,并试图充分利用生活,这影响了他们对未满足需求的认知。

结论

在r/r和反复治疗的漫长过程中,iNHL患者接受了较低的HRQOL,珍视他们目前的状况,并努力充分利用生活。在这种情况下,心理、医疗系统和信息领域的支持至关重要。支持r/r iNHL患者满足未满足的需求至关重要,因为他们在努力过上最好生活的同时,还要维持良好的HRQOL。

相似文献

1
Unmet Needs and Health-Related Quality of Life Among Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: A Mixed-Methods Study.复发/难治性惰性非霍奇金淋巴瘤患者未满足的需求及与健康相关的生活质量:一项混合方法研究
Psychooncology. 2025 Feb;34(2):e70103. doi: 10.1002/pon.70103.
2
Unmet needs of non-Hodgkin lymphoma survivors in Korea: prevalence, correlates, and associations with health-related quality of life.韩国非霍奇金淋巴瘤幸存者未满足的需求:患病率、相关因素及其与健康相关生活质量的关联
Psychooncology. 2017 Mar;26(3):330-336. doi: 10.1002/pon.4136. Epub 2016 Apr 13.
3
Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study.非霍奇金淋巴瘤幸存者的健康相关生活质量:一项前瞻性队列研究。
Cancer Res Treat. 2018 Oct;50(4):1051-1063. doi: 10.4143/crt.2017.207. Epub 2017 Nov 9.
4
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.马吉妥昔单抗联合利妥昔单抗治疗复发/难治性惰性非霍奇金淋巴瘤:一项 1/2 期试验的 3 年随访结果。
Blood Adv. 2024 Nov 26;8(22):5855-5863. doi: 10.1182/bloodadvances.2024013277.
5
Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.硼替佐米、克拉屈滨和利妥昔单抗用于晚期、新诊断及复发/难治性套细胞淋巴瘤和惰性淋巴瘤的2期开放标签研究。
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):58-64. doi: 10.1016/j.clml.2017.09.001. Epub 2017 Sep 19.
6
Health-related quality of life and unmet healthcare needs in Huntington's disease.亨廷顿舞蹈症患者与健康相关的生活质量及未满足的医疗需求
Health Qual Life Outcomes. 2017 Jan 7;15(1):6. doi: 10.1186/s12955-016-0575-7.
7
Perceived unmet needs and health-related quality of life of Chinese cancer survivors at 1 year after treatment.癌症患者治疗 1 年后的未满足需求及健康相关生活质量的认知。
Cancer Nurs. 2013 May-Jun;36(3):E23-32. doi: 10.1097/NCC.0b013e318263f28e.
8
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.来分析 AUGMENT 三期研究中来自日本的患者数据,该研究比较了来那度胺 + 利妥昔单抗(R)与利妥昔单抗 + 安慰剂在复发性/难治性惰性非霍奇金淋巴瘤中的疗效。
Int J Hematol. 2020 Mar;111(3):409-416. doi: 10.1007/s12185-019-02802-y. Epub 2019 Dec 19.
9
The unmet needs of patients with sarcoma.肉瘤患者的未满足需求。
Psychooncology. 2020 Jul;29(7):1209-1216. doi: 10.1002/pon.5411. Epub 2020 Jun 16.
10
Cancer-related information needs and cancer's impact on control over life influence health-related quality of life among adolescents and young adults with cancer.与癌症相关的信息需求以及癌症对生活掌控的影响,会影响患有癌症的青少年和青年的健康相关生活质量。
Psychooncology. 2015 Sep;24(9):1104-15. doi: 10.1002/pon.3730. Epub 2015 Jan 21.

本文引用的文献

1
Fear of progression after cancer recurrence: a mixed methods study.癌症复发后对病情进展的恐惧:一项混合方法研究。
Front Psychol. 2024 Sep 25;15:1479540. doi: 10.3389/fpsyg.2024.1479540. eCollection 2024.
2
Quality of Life Evaluation in Patients with Follicular Cell Lymphoma: A Real-World Study in Europe and the United States.滤泡细胞淋巴瘤患者的生活质量评估:欧洲和美国的真实世界研究。
Adv Ther. 2024 Aug;41(8):3342-3361. doi: 10.1007/s12325-024-02882-1. Epub 2024 Jul 8.
3
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
4
Post-traumatic growth in cancer survivors: What is its extent and what are important determinants?癌症幸存者的创伤后成长:其程度如何以及重要的决定因素有哪些?
Int J Clin Health Psychol. 2024 Jan-Mar;24(1):100418. doi: 10.1016/j.ijchp.2023.100418. Epub 2023 Oct 14.
5
Marginal zone lymphoma: 2023 update on diagnosis and management.边缘区淋巴瘤:2023年诊断与管理更新
Am J Hematol. 2023 Oct;98(10):1645-1657. doi: 10.1002/ajh.27058. Epub 2023 Aug 21.
6
Global burden of hematologic malignancies and evolution patterns over the past 30 years.全球血液系统恶性肿瘤负担及过去 30 年的演变模式。
Blood Cancer J. 2023 May 17;13(1):82. doi: 10.1038/s41408-023-00853-3.
7
Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis.≥2 线治疗后复发/难治滤泡性淋巴瘤患者的临床结局:系统文献回顾和荟萃分析。
BMC Cancer. 2023 Jan 23;23(1):74. doi: 10.1186/s12885-023-10546-6.
8
On a pathway to resigned acceptance: Patients' experiences of living with symptom clusters in oral cancer.在无奈接受的道路上:口腔癌患者经历症状群的体验。
Eur J Oncol Nurs. 2023 Feb;62:102263. doi: 10.1016/j.ejon.2022.102263. Epub 2022 Dec 19.
9
Follicular lymphoma: 2023 update on diagnosis and management.滤泡性淋巴瘤:2023 年诊断和管理更新。
Am J Hematol. 2022 Dec;97(12):1638-1651. doi: 10.1002/ajh.26737. Epub 2022 Oct 18.
10
Living with or beyond lymphoma: A rapid review of the unmet needs of lymphoma survivors.与淋巴瘤共存或超越淋巴瘤:淋巴瘤幸存者未满足需求的快速综述。
Psychooncology. 2022 Jul;31(7):1076-1101. doi: 10.1002/pon.5973. Epub 2022 Jun 27.